Patient demographics and baseline disease characteristics: intent-to-treat population.
| Characteristics | Overall, n = 120 | Canada, n = 91 | Sweden, n = 29 |
|---|---|---|---|
| Age, yrs, mean ± SD | 55.6 ± 10.20 | 54.8 ± 9.59 | 58.3 ± 11.70 |
| Men/women, % | 27.5/72.5 | 25.3/74.7 | 34.5/65.5 |
| Race, n | |||
| White | 113 | 84 | 29 |
| Black | 1 | 1 | 0 |
| Asian | 1 | 1 | 0 |
| Other | 5 | 5 | 0 |
| RA duration, yrs, mean ± SD | 13.9 ± 9.78 | 13.6 ± 8.96 | 15.2 ± 12.09 |
| TJC, mean ± SD | 16.1 ± 6.62 | 17.4 ± 6.66 | 12.0 ± 4.59 |
| SJC, mean ± SD | 13.7 ± 5.33 | 14.4 ± 5.40 | 11.5 ± 4.54 |
| DAS28, mean ± SD | 6.4 ± 1.06 | 6.5 ± 1.10 | 6.2 ± 0.93 |
| HAQ-DI, mean ± SD | 1.7 ± 0.57 | 1.8 ± 0.55 | 1.4 ± 0.51 |
| Global assessment of pain, mean ± SD | 60.2 ± 22.85 | 62.6 ± 22.83 | 52.8 ± 21.62 |
| Global assessment of disease activity, mean + SD | 67.5 ± 22.73 | 69.0 ± 23.57 | 62.8 ± 22.32 |
| FACIT-F, mean ± SD | 28.9 ± 10.22 | 30.1 ± 10.52 | 25.2 ± 8.31 |
| RF+, n (%) | 89 (74.2) | 66 (72.5) | 23 (79.3) |
| CRP, mg/dl | 25.6 | 24.2 | 30.1 |
| ESR, mm/h | 37.0 | 34.5 | 44.8 |
CRP: C-reactive protein; DAS28: 28-joint count Disease Activity Score; HAQ-DI: Health Assessment Questionnaire Disability Index; RA: rheumatoid arthritis; RF+: rheumatoid factor-positive; SJC: swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue.